The cause(s) of sporadic Alzheimer's disease (sAD) 
Introduction

Alzheimer's disease (AD) is an age-related neurodegenerative disorder, which is characterized by progressive memory loss and behavioural changes that become more apparent and more severe as the disease progresses, and accounts for up to 70% of all dementias. Underlying these phenotypic changes are the appearance of several hallmark pathologies. The first is the accumulation of the amyloid-␤ peptide (A␤) into extracellular plaques, whereas the second is the formation of neurofibrillary tangles (NFTs) composed of hyperphosphorylated protein within neurons
. The consequence of the development of these two pathologies is widespread synaptic and neuronal loss, such that a brain with advanced [2, 3] , [4, 5] , presenilin 1 (PS1) gene [6] and presenilin 2 (PS2) gene [7] . APP is a large membrane spanning protein that contains the A␤ peptide sequence [4] . A␤ is sequentially cleaved from APP. An enzyme identified as BACE first cleaves APP [8] to produce a 99 amino acid stub within the membrane known as C99. C99 is then cleaved by a complex known as ␥-secretase to release A␤ [9, 10] [12] , whereas mutations in APP are associated with increased BACE cleavage [13] , A␤ structural misfolding [14] , or an increased prevalence of A␤1-42 at the expense of shorter A␤ peptides [15] . [72] , and proteasome inhibition increases levels of both and A␤ in vivo [73] . Notably, autophagy is crucial for the removal of cytosolic aggregates especially those implicated in neurodegenerative diseases [74] . Age [85] and IP3 receptor binding [86] , in cases with high pathology, suggesting that either NFT formation downregulates these calcium pumps which may contribute to neurodegeneration, or that a down-regulation of these pumps (perhaps by A␤ pathologies) encourages NFT formation.
AD can weigh 33% less than a brain from an aged-matched control. AD research has focused on two main areas -the first is in understanding what causes the accumulation of these two pathologies in the aged brain, and the second is understanding how the presence of these pathologies affects the local brain environment to cause the widespread synaptic and neuronal loss, and cognitive decline. Through understanding, it is possible that (1) the accumulation of pathologies in the aged brain can be delayed, prevented, or even reversed, and that (2) the neurodegenerative properties of the pathologies can be dampened. Over the past 20 years aberrant calcium dysregulation has been consistently implicated in AD
calbindin), and via the extrusion of cytosolic calcium across the plasma membrane through calcium ATPase pumps and exchangers, and also due to sequestration into intracellular stores such as the endoplasmic reticulum (ER) and mitochondria. Calcium influx into the cytosol occurs across the plasma membrane via store-operated calcium channels, voltage-gated calcium channels or from internal stores. The ER is the largest intracellular store, maintaining a high calcium concentration (100-500 M) via the unidirectional pumping of cytosolic calcium into the ER lumen by SERCA. Calcium release from the ER into the cytosol occurs via two types of calcium channels: IP3Rs and RyRs. IP3R-mediated release is regulated at the plasma membrane by ligand binding to specific G-protein coupled receptors that induce phospholipase C to cleave phosphatidylinositol-4, 5-bisphosphate into diacylglycerol and IP3, which then binds to the IP3R in the ER membrane. Calcium influx across the plasma membrane occurs due to depolarization, through VGCCs, and glutamate receptors such as the NMDA receptor and the mGluR.
Familial and sporadic AD
The overwhelming majority of AD cases occurs with no obvious environmental or genetic cause and is known as sporadic AD (sAD). It typically manifests at a late age of onset of more than 65 years. Around 5% of all AD cases, however, have a Mendelian pattern of inheritance and these are referred to as familial AD (fAD). The age of onset of dementia in fAD can vary dramatically, but typically fAD cases occur at much younger ages (from 30 years or more), and their dementia is usually
Calcium, calpains and pathology A␤ induced increases in calcium lead to hyperphosphorylation via both GSK3␤ and Cdk5 [87] . Cdk5 activity is regulated through its interactions with cyclin-related activator molecules such as p25, p35, p29 and p39. A␤ increases the activity of Cdk5 by promoting the Cdk5-p25 and p35 complexes [88] [89] [90] . p39/p35 is cleaved to p29/25 by calpains [91] , releasing it from a membrane tether where it forms unregulated functional complexes with Cdk5 leading to hyperphosphorylation [92] . Activation of calpain is calcium dependent, and aberrant activation of calpains 1 and 2 has been linked to AD [93, 94] . Calpain 2 has increased activation in NFT bearing neurons and neurites [95] , whereas a calpain substrate, calcineurin, is truncated in the AD brain [96] . Hence, A␤-mediated and age related increases in cytosolic calcium can lead to the activation of calpains, which then lead to hyperphosphorylation of via Cdk5 [97] . Of note, a recent study highlighted how calpain activation in transgenic mouse models of AD leads to synaptic dysfunction and behavioural impairments [98] . Calpain 1 is expressed in dendritic spines [99] , which have abnormally elevated basal calcium levels in close proximity to A␤ plaques [100] [137] , as well as in mouse models of AD [138] , cell culture models of A␤ toxicity via attenuation of phosphorylation [139] , and is also associated with a reduction in A␤ plaque pathology [140] .
Calcium as a disease effector
The discovery of a polymorphism in the CALHM1 gene, linking calcium influx to A␤ generation and an increased risk of developing AD provided concrete evidence for a role for calcium in the initiation of sAD [34], but so far three further linkage studies have failed to replicate the association to sAD [35-37]. Despite this, the evidence that age-related changes in neuronal calcium homeostasis could affect APP processing and A␤ metabolism is compelling and offers potential therapeutic targets to try and reverse these changes in calcium, and hence APP processing. However, the appearance of A␤ in old age is only the first step in neurodegeneration and dementia, and there is overwhelming evidence that (1) A␤ induces disturbances in neuronal and synaptic calcium homeostasis and (2) that such changes in neuronal and
Synaptic calcium dyshomeostasis and AD -a focus on NMDA receptors Synaptic loss is the best correlate to dementia in the AD brain, although A␤ and loads associate poorly with dementia. In addition to this, work with transgenic mouse models, which overexpress A␤, has shown that A␤ induces memory and LTP impairments without overt neuronal loss, and can do so in an acute fashion. As such the site of neuronal plasticity, the synapse, is highlighted as a crucial target for the A␤ peptide as disturbances
Other calcium influx pathway blockers have also been evaluated in AD patients, although without sustained efficacy, including the L-type voltage gated calcium channel blocker nimodipine [141] , and other calcium channel blockers associated with the cardiovascular system [142] . Dimebon, an antihistamine, has been shown to improve cognition in mild to moderate AD patients [143] , and has reported activity as an NMDA receptor antagonist, as well being able to block voltage gated calcium channel currents, although at concentrations that may be too high to be responsible for the improvements in cognition [144] 
